The Hemostatic Effect of T-Hemocel in Neurosurgery Case
Andi Asadul Islam
Perfil de Orcid, Juliani Ibrahim
Perfil de Orcid y 
Publicado en línea: 17 nov 2024
Páginas: 370 - 374
Recibido: 21 nov 2023
Aceptado: 21 may 2024
DOI: https://doi.org/10.3889/oamjms.2024.11834
Palabras clave
© 2024 Andi Asadul Islam et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License.
BACKGROUND
Decompressive craniectomy (DC) is a neurosurgical procedure associated with significant blood loss. Effective hemostatic agents can minimize blood loss and improve surgical outcomes. T- Hemocel, a hemostatic agent composed of oxidized regenerated cellulose, is increasingly used in neurosurgery, but its efficacy in DC requires further investigation.
AIM
This study aimed to evaluate the hemostatic efficacy of T-Hemocel in patients undergoing DC.
METHODS
A retrospective chart review was conducted on ten (10) patients who underwent DC at our institution between July 2019 and August 2019. Data on patient demographics, time to hemostasis, and surgical complications were collected. Due to the limited sample size, a control group receiving a different hemostatic agent was not included.
RESULTS
All ten patients who received T-Hemocel during DC achieved hemostasis within 10 min of administration. No surgical bleeding incidents were reported. This retrospective analysis suggests that T-Hemocel may be a viable hemostatic option in DC, with all patients achieving hemostasis within 10 min. However, the small sample size limits the generalizability of these findings.
CONCLUSION
Future studies with larger sample sizes and potentially including a control group are warranted to confirm these observations and explore the efficacy of T-Hemocel in a broader range of neurosurgical procedures.